REA
Candidate Overview
A multifusion protein-based vaccine formulated with MPL/DDA.
Sponsor / Lead Developer: Myco-Rapha Inc. and Chungnam National University (South Korea)
Primary Indication: Prevention of TB disease
Other Indication(s): Prevention of Mtb infection or sustained infection
Target Population(s): Adolescents, Adults, Elderly, and People with Mtb infection
Target Route of Administration: Intramuscular
Immune tissue localization: Lung, Lymph node, and Spleen
Immunological responses: T-cell
Preclinical Animal Models: Guinea pig and Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ TNF-α IL-17 Polycytotoxicity Mycobacterial growth inhibition |
|
| Preferential immune tissue localization | Lung Lymph node Spleen |
|
| Trained immunity | No | |
Related Publications
- Novel fusion protein REA induces robust prime protection against tuberculosis in mice. (NPJ Vaccines, 2025)